Status:
COMPLETED
Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients
Lead Sponsor:
Damanhour University
Conditions:
Breast Cancer
Chemotherapeutic Toxicity
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients
Detailed Description
Fifty female patients with newly diagnosed breast cancer scheduled for weekly paclitaxel chemotherapy (80 mg/m2) will be randomized in a 1:1 ratio. The CoQ10 Group will receive Coenzyme Q10 supplement...
Eligibility Criteria
Inclusion
- women with newly diagnosed breast cancer r ≥18 years old.
- Naive to chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status from 0-2
Exclusion
- Advanced liver disease (defined as liver enzyme elevation \>3-fold upper limit of normality, or cirrhosis); chronic kidney disease (CKD, defined as an estimated glomerular filtration rate (eGFR) \<60 ml min-1 1.73 m-2).
- Patients with a history of allergy to Coenzyme Q10 and similar compounds.
- Concomitant use of opioids, anticonvulsants, tricyclic antidepressants, other neuropathic pain medication.
- Pregnancy or breast feeding.
- hereditary muscle disorders.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06570811
Start Date
August 1 2024
End Date
March 30 2025
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damanhour Oncology Center
Damanhūr, Egypt, 22511